A phase II study of savolitinib in Chinese patients with NSCLC harboring MET exon 14 skipping mutation showed that the incidence of grade ≥ 3 TRAEs was 46%, with the most common being increased AST (13%), increased ALT (10%) and peripheral oedema (9%) [15]. The gene discussed is GPT; the disease is non-small cell lung carcinoma.